Y
Yunda Huang
Researcher at Fred Hutchinson Cancer Research Center
Publications - 86
Citations - 3694
Yunda Huang is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 20, co-authored 64 publications receiving 3019 citations. Previous affiliations of Yunda Huang include HIV Vaccine Trials Network & University of Washington.
Papers
More filters
Journal ArticleDOI
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes,Peter B. Gilbert,M. Juliana McElrath,Susan Zolla-Pazner,Georgia D. Tomaras,S. Munir Alam,David T. Evans,David C. Montefiori,Chitraporn Karnasuta,Ruengpueng Sutthent,Hua-Xin Liao,Anthony L. DeVico,George K. Lewis,Constance Williams,Abraham Pinter,Youyi Fong,Holly Janes,Allan C. deCamp,Yunda Huang,Mangala Rao,Erik Billings,Nicos Karasavvas,Merlin L. Robb,Viseth Ngauy,Mark de Souza,Robert Paris,Guido Ferrari,Robert T. Bailer,Kelly A. Soderberg,Charla Andrews,Phillip W. Berman,Nicole Frahm,Stephen C. De Rosa,Michael D. Alpert,Nicole L. Yates,Xiaoying Shen,Richard A. Koup,Punnee Pitisuttithum,Jaranit Kaewkungwal,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Nelson L. Michael,Jerome H. Kim +42 more
TL;DR: V vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.
Journal ArticleDOI
Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study)
Ann Duerr,Yunda Huang,Susan Buchbinder,Robert W. Coombs,Jorge Sanchez,Carlos del Rio,Martin Casapia,Steven Santiago,Peter B. Gilbert,Lawrence Corey,Michael N. Robertson,Hvtn Study Team +11 more
TL;DR: The vaccine-associated risk seen in interim analysis was confirmed but waned with time from vaccination, and nonparametric and semiparametric methods for analysis of constancy of relative risk over time were used.
Journal ArticleDOI
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine
Nicole Frahm,Allan C. deCamp,David Friedrich,Donald K. Carter,Olivier D. Defawe,James G. Kublin,Danilo R. Casimiro,Ann Duerr,Michael N. Robertson,Susan Buchbinder,Yunda Huang,Gregory A. Spies,Stephen C. De Rosa,M. Juliana McElrath +13 more
TL;DR: This work has identified and compared adenovirus-specific and HIV-specific T cell responses in subjects participating in two HIV-1 vaccine trials using a vaccine vectored by adenvirus serotype 5 (Ad5), and provides what it believes to be a new understanding of how preexisting viral immunity may impact the efficacy of vaccines.
Journal ArticleDOI
Preservation of T Cell Proliferation Restricted by Protective HLA Alleles Is Critical for Immune Control of HIV-1 Infection
Helen Horton,Ian Frank,Ruth Baydo,Emilie Jalbert,Justin Penn,Sean Wilson,John McNevin,Matthew D. McSweyn,Deborah Lee,Yunda Huang,Stephen C. De Rosa,M. Juliana McElrath +11 more
TL;DR: The capacity to maintain CD8+ T cell proliferation, regardless of MHC-restriction, may serve as an important correlate of disease protection in the event of infection following vaccination.
Journal ArticleDOI
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Kenneth H. Mayer,Kelly E. Seaton,Yunda Huang,Nicole Grunenberg,Abby Isaacs,Mary Allen,Julie E. Ledgerwood,Ian Frank,Magdalena E. Sobieszczyk,Lindsey R. Baden,Benigno Rodriguez,Hong Van Tieu,Georgia D. Tomaras,Aaron Deal,Derrick Goodman,Robert T. Bailer,Guido Ferrari,Ryan L. Jensen,John Hural,Barney S. Graham,John R. Mascola,Lawrence Corey,David C. Montefiori +22 more
TL;DR: VRC01 administered as either an IV infusion given monthly or bimonthly, or as an SC injection every 2 weeks, was found to be safe and well tolerated and VRC01 concentrations from participants’ sera were found to avidly capture HIV virions.